Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01347333 · ClinicalTrials.gov registry record · NA
Stereotactic Body Radiotherapy for Liver Tumors
A NA study, sponsored by Mercy Research.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT01347333: Completed NA study, sponsored by Mercy Research.
NCT01347333 is a NA study that has completed, run by Mercy Research. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01347333, a NA study, has completed, sponsored by Mercy Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Primary Outcome
Primary endpoint will be local tumor recurrence rate. Local recurrence is defined as tumor recurrence within the planning target volume.
Interventions
- RADIATION Stereotactic Body Radiotherapy
- RADIATION Stereotactic body radiosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-09 |
| Est. Completion | 2016-09 |
| Phase | NA |
What the finished NCT01347333 record still lists
NCT01347333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiotherapy is the first listed.
NCT01347333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01347333 about?
NCT01347333 is a clinical study titled "Stereotactic Body Radiotherapy for Liver Tumors". This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
What is the current status of trial NCT01347333?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2008-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01347333?
The interventions under investigation include: Stereotactic Body Radiotherapy (RADIATION), Stereotactic body radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT01347333?
This trial is sponsored by Mercy Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01347333's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia